SIGA Technologies (SIGA) Company Overview

In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $6.34, denoting a -1.71% change from the preceding trading day.

In the latest trading session, Siga Technologies Inc. (SIGA) finished at $6.47, showing an increase of 1.25% compared to the day before.

In the most recent trading session, Siga Technologies Inc. (SIGA) closed at $6.47, indicating a +1.25% shift from the previous trading day.

The latest trading day saw Siga Technologies Inc. (SIGA) settling at $6.35, representing a +0.32% change from its previous close.

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as TPOXX in the United States, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. TEPOXX is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency (PMDA), in collaboration with the Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Siga Technologies (SIGA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga's long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox.